Difference between revisions of "Degarelix (Firmagon)"
m (updated links) |
m |
||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*12/24/2008: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129207.htm FDA approved] for treatment of patients with advanced [[prostate cancer]]. ''(Based on CS21)'' | *12/24/2008: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129207.htm FDA approved] for treatment of patients with advanced [[prostate cancer]]. ''(Based on CS21)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *2/17/2009: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' ASP3550, FE200486 | *'''Code name:''' ASP3550, FE200486 | ||
| Line 32: | Line 33: | ||
[[Category:FDA approved in 2008]] | [[Category:FDA approved in 2008]] | ||
| + | [[Category:FDA approved in 2009]] | ||
Revision as of 13:58, 31 December 2022
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Degarelix (Firmagon) package insert[1]
- Degarelix (Firmagon) patient drug information (Chemocare)[4]
- Degarelix (Firmagon) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 12/24/2008: FDA approved for treatment of patients with advanced prostate cancer. (Based on CS21)
History of changes in EMA indication
- 2/17/2009: Initial authorization
Also known as
- Code name: ASP3550, FE200486
- Generic name: degarelix acetate
- Brand name: Firmagon